These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2150522)

  • 1. Incidence of severe ovarian hyperstimulation syndrome after GnRH agonist/HMG superovulation for in-vitro fertilization.
    Smitz J; Camus M; Devroey P; Erard P; Wisanto A; Van Steirteghem AC
    Hum Reprod; 1990 Nov; 5(8):933-7. PubMed ID: 2150522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
    Seyhan A; Ata B; Polat M; Son WY; Yarali H; Dahan MH
    Hum Reprod; 2013 Sep; 28(9):2522-8. PubMed ID: 23633553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized comparative study of purified follicle stimulating hormone and human menopausal gonadotropin after pituitary desensitization with Buserelin for superovulation and in vitro fertilization.
    Bentick B; Shaw RW; Iffland CA; Burford G; Bernard A
    Fertil Steril; 1988 Jul; 50(1):79-84. PubMed ID: 3133251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
    Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
    Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The luteal phase and early pregnancy after combined GnRH-agonist/HMG treatment for superovulation in IVF or GIFT.
    Smitz J; Devroey P; Camus M; Deschacht J; Khan I; Staessen C; Van Waesberghe L; Wisanto A; Van Steirteghem AC
    Hum Reprod; 1988 Jul; 3(5):585-90. PubMed ID: 3139698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled ovarian hyperstimulation for in vitro fertilization using buserelin and gonadotropin in patients with previous failed cycles.
    Loong EP; Tam PP; Chiu TT; Chan MY; Panesar NS; Lau J
    Asia Oceania J Obstet Gynaecol; 1990 Dec; 16(4):297-300. PubMed ID: 2129187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pituitary gonadotrophin secretory capacity during the luteal phase in superovulation using GnRH-agonists and HMG in a desensitization or flare-up protocol.
    Smitz J; Erard P; Camus M; Devroey P; Tournaye H; Wisanto A; Van Steirteghem AC
    Hum Reprod; 1992 Oct; 7(9):1225-9. PubMed ID: 1479002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationships between the characteristics of endogenous luteinizing hormone surge and the degree of ovarian hyperstimulation during superovulation induction in women.
    Messinis IE; Templeton A; Baird DT
    Clin Endocrinol (Oxf); 1986 Oct; 25(4):393-400. PubMed ID: 3113775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of dehydroepiandrosterone sulfate as a prehormone for ovarian steroidogenesis.
    Haning RV; Austin CW; Carlson IH; Kuzma DL; Zweibel WJ
    Obstet Gynecol; 1985 Feb; 65(2):199-205. PubMed ID: 3155830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
    Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
    Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Increased incidence of ovarian hyperstimulation syndrome following combined GnRH agonist/hMG therapy].
    Lindner C; Braendle W; Köhler S; Bettendorf G
    Geburtshilfe Frauenheilkd; 1989 Apr; 49(4):337-44. PubMed ID: 2525500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is continuation of a gonadotrophin-releasing hormone agonist (GnRHa) necessary for women at risk of developing the ovarian hyperstimulation syndrome?
    Wada I; Matson PL; Horne G; Buck P; Lieberman BA
    Hum Reprod; 1992 Sep; 7(8):1090-3. PubMed ID: 1400932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
    Krause BT; Ohlinger R
    Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GnRH agonist trigger with intensive luteal phase support vs. human chorionic gonadotropin trigger in high responders: an observational study reporting pregnancy outcomes and incidence of ovarian hyperstimulation syndrome.
    Christopoulos G; Vlismas A; Carby A; Lavery S; Trew G
    Hum Fertil (Camb); 2016 Sep; 19(3):199-206. PubMed ID: 27662416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of ovarian stimulation regimens for in vitro fertilization (IVE) with and without a gonadotropin-releasing hormone (GnRH) agonist: results of a randomized study.
    van de-Helder AB; Helmerhorst FM; Blankhart A; Brand R; Waegemaekers C; Naaktgeboren N
    J In Vitro Fert Embryo Transf; 1990 Dec; 7(6):358-62; discussion 363-4. PubMed ID: 2127604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superovulation strategy before in vitro fertilization.
    Hillier SG; Afnan AM; Margara RA; Winston RM
    Clin Obstet Gynaecol; 1985 Sep; 12(3):687-723. PubMed ID: 3933880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovulation induction with human menopausal gonadotropin compared to human urinary follicle-stimulating hormone results in a significant shift in follicular fluid androgen levels without discernible differences in granulosa-luteal cell function.
    Polan ML; Daniele A; Russell JB; DeCherney AH
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1284-91. PubMed ID: 3097055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of the GnRH analog buserelin on sex hormone serum level in relation to treatment onset and duration].
    Urbancsek J; Rabe T; Gör U; Schulte B; Grunwald K; Papp Z; Runnebaum B
    Geburtshilfe Frauenheilkd; 1991 Aug; 51(8):617-25. PubMed ID: 1834511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.